On Wednesday, Shares of Cisco Systems, Inc. (NASDAQ:CSCO), lost -0.40% to $27.35.
Cisco Systems, declared its intent to acquire OpenDNS, a privately held security company based in San Francisco. OpenDNS provides advanced threat protection for any device, anywhere, anytime. The acquisition will boost Cisco’s Security Everywhere approach by adding broad visibility and threat intelligence from the OpenDNS cloud delivered platform.
The burgeoning digital economy and the Internet of Everything (IoE) are predictable to spur the connection of nearly 50 billion devices by 2020, creating a vast new wave of opportunities for security breaches across networks. The faster customers can deploy a solution, the faster they can detect, block and remediate these emerging security threats. OpenDNS’ cloud platform offers security delivered in a Software-as-a- Service (SaaS) model, making it quick and easy for customers to deploy and integrate as part of their defense architecture or incident response strategies. By providing comprehensive threat awareness and pervasive visibility, the combination of Cisco and OpenDNS will enhance advanced threat protection across the full attack continuum — before, during and after an attack.
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide. It provides switching products, counting fixed-configuration and modular switches, and storage products that provide connectivity to end users, workstations, IP phones, wireless access points, and servers; and NGN routing products that interconnect public and private wireline and mobile networks for mobile, data, voice, and video applications.
Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), inclined 0.17% to $32.60, during its last trading session.
On June 25, Brian Sullivan, who served for the past five years as the CEO of Sky Deutschland, will join 21st Century Fox in a senior capacity as President of Digital for Fox Networks Group (FNG), a new role within the Company. Mr. Sullivan will be based in Los Angeles and start his duties on July 27.
The declaration was made by Peter Rice, Chairman and CEO of FNG, to whom Mr. Sullivan will report.
As President of Digital, Mr. Sullivan will be responsible for both coordinating strategy in the direct-to-consumer digital video category, and driving growth across FNG’s outstanding portfolio of products, which comprise FOXNow, FXNow, FOX Sports Go and the group’s international Fox Play products, among others. He will also collaborate closely with Randy Freer, President and COO of FNG, and the leadership of FNG’s channels – John Landgraf, Hernan Lopez, Courteney Monroe, Gary Newman, Dana Walden, and Eric Shanks – to assist develop a single global commercial platform to further empower the businesses to harness digital opportunities around data, monetization and ad serving.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming, Television, Filmed Entertainment, and Direct Broadcast Satellite Television segments.
Finally, TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), ended its last trade with 0.85% gain, and closed at $2.36.
TetraLogic Pharmaceuticals Corporation, declared preliminary data from the ongoing Phase 2A study of birinapant in combination with azacitidine in first line higher risk myelodysplastic syndromes (MDS). The study is being conducted as a precursor to the ongoing randomized Phase 2B study.
In this study, birinapant was administered, at 13 mg/m2 twice a week, three weeks out of four, during a four week cycle in combination with the approved dose of azacitidine. The primary assessment of efficacy was the response rate using the modified International Working Group criteria (Cheson 2006) at the end of cycle four. Of the nine patients who entered the study, six accomplished four cycles of therapy and underwent a repeat bone marrow assessment. Three patients practiced a complete response, one patient practiced a bone marrow complete response, one patient practiced a partial response and underwent a stem cell transplant and one patient had stable disease. Three patients suspended the study preceding to receiving four cycles of treatment. The regimen was generally well tolerated, the most common side effects being fatigue, neutropenia and thrombocytopenia.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
